HPV Vaccine and Screening Strategy for Cervical Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to explore strategies for preventing cervical cancer by encouraging HPV (human papillomavirus) vaccination and improving screening methods. Participants will help researchers understand what influences women's decisions to participate in self-sample HPV testing and follow-up diagnostics. Women aged 25 and older who haven't had a Pap test in the last 3.5 years or a Pap/HPV co-test in the last 5.5 years, and who live in low-resource areas in Texas, might be a good fit.
As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could shape future cervical cancer prevention strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this screening strategy is safe for cervical cancer prevention?
Research has shown that the PRECEDE-PROCEED model improves health programs, such as those for preventing cervical cancer. Safety is not a primary concern because this model focuses on planning and evaluating health programs, not on testing new drugs or vaccines. It ensures that health programs, like HPV screening, are effective and meet quality standards.
The PRECEDE-PROCEED approach has been used in many health projects, with no direct safety issues reported. Instead, it identifies factors that might encourage or discourage people from using health services like HPV testing. As a method to enhance health strategies rather than a treatment, it carries no known safety risks.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores a novel approach to cervical cancer prevention through the PRECEDE-PROCEED model. Unlike traditional methods that focus solely on medical interventions, this strategy looks at the bigger picture by identifying behavioral and environmental factors that influence women's decisions to participate in HPV self-sampling and follow-up diagnostics. This comprehensive approach has the potential to empower women, increase participation in early screening, and ultimately improve cervical cancer prevention outcomes.
What evidence suggests that this trial's treatments could be effective for cervical cancer?
Research has shown that the PRECEDE-PROCEED model, tested in this trial, increases cervical cancer screening. One study found that this model identifies factors that encourage women to participate in HPV testing and follow-up care. Another study demonstrated that educational programs using this model improved women's knowledge and habits for preventing cervical cancer. Additionally, mailing HPV testing kits, guided by this model, increased screening participation. Overall, this approach helps more women get screened, which is crucial for preventing cervical cancer.13678
Who Is on the Research Team?
Jane Montealegre
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for women aged 30 or older living in RGV who haven't had a Pap test in the last 3.5 years or a Pap/HPV co-test in the past 5.5 years, and have not been diagnosed with cervical cancer or severe cervical dysplasia. Participants must be able to understand English or Spanish, are not pregnant, and do not belong to vulnerable populations.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Community-Based Intervention
Community Health Workers (CHW) deliver self-sample HPV testing to increase cervical cancer screening among women
Follow-up
Participants who test positive for HR-HPV are monitored for clinical follow-up and further diagnostic procedures
What Are the Treatments Tested in This Trial?
Interventions
- PRECEDE-PROCEED
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor